- Home
- BTBT vs MRSN Comparison
BTBT vs MRSN Comparison
Compare BTBT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- MRSN
- Stock Information
- Founded
- BTBT 2015
- MRSN 2001
- Country
- BTBT United States
- MRSN United States
- Employees
- BTBT N/A
- MRSN N/A
- Industry
- BTBT Finance: Consumer Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- MRSN Health Care
- Exchange
- BTBT Nasdaq
- MRSN Nasdaq
- Market Cap
- BTBT 418.3M
- MRSN 191.4M
- IPO Year
- BTBT 2018
- MRSN 2017
- Fundamental
- Price
- BTBT $2.47
- MRSN $1.35
- Analyst Decision
- BTBT Strong Buy
- MRSN Buy
- Analyst Count
- BTBT 2
- MRSN 6
- Target Price
- BTBT $6.00
- MRSN $6.00
- AVG Volume (30 Days)
- BTBT 10.5M
- MRSN 1.1M
- Earning Date
- BTBT 08-19-2024
- MRSN 11-05-2024
- Dividend Yield
- BTBT N/A
- MRSN N/A
- EPS Growth
- BTBT N/A
- MRSN N/A
- EPS
- BTBT 0.27
- MRSN N/A
- Revenue
- BTBT $86,851,522.00
- MRSN $29,937,000.00
- Revenue This Year
- BTBT $199.51
- MRSN N/A
- Revenue Next Year
- BTBT $39.83
- MRSN $6.96
- P/E Ratio
- BTBT $9.17
- MRSN N/A
- Revenue Growth
- BTBT 153.87
- MRSN N/A
- 52 Week Low
- BTBT $1.76
- MRSN $1.07
- 52 Week High
- BTBT $5.27
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- BTBT 33.66
- MRSN 39.28
- Support Level
- BTBT $2.75
- MRSN $1.44
- Resistance Level
- BTBT $3.87
- MRSN $1.61
- Average True Range (ATR)
- BTBT 0.26
- MRSN 0.12
- MACD
- BTBT -0.10
- MRSN 0.01
- Stochastic Oscillator
- BTBT 0.36
- MRSN 23.08
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries.. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. It generates revenue from digital asset mining and ETH staking business.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.